Sponsor intelligence · OTHER
Clinical trials sponsored by
Fudan University.
Real, source-linked trial activity for Fudan University: 23 tracked trials, by phase and status, newest first. New trials = pipeline expansion = CRO, site, and reagent demand.
✔ Verified against the public NIH RePORTER & ClinicalTrials.gov records as of Nov 4, 2026. Source-linked, daily-refreshed.
PHASE2 10N/A 6NA 5PHASE3 2
Newest Fudan University trials
| Posted | Trial | Phase | Status | |
|---|---|---|---|---|
| 1d ago | China HEalthy Aging and Dementia Study (HEAD) | N/A | RECRUITING | ↗ |
| 15d ago | Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoad | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 19d ago | Chemotherapy Combined With or Without Short-Course Radiotherapy Versus | Ph 3 | NOT_YET_RECRUITING | ↗ |
| 20d ago | MAMMI-BB PET for Monitoring Response to Neoadjuvant Therapy in Breast | NA | ACTIVE_NOT_RECRUITING | ↗ |
| 21d ago | Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemothera | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 21d ago | Artificial Intelligence-assisted Primary Care for Influenza Vaccinatio | NA | NOT_YET_RECRUITING | ↗ |
| 29d ago | Hemodynamic Characteristics of Peripheral Arterial Disease Using Compu | N/A | NOT_YET_RECRUITING | ↗ |
| 33d ago | Vaccine Knowledge, Attitudes and Practices Among Men Who Have Sex With | N/A | NOT_YET_RECRUITING | ↗ |
| 33d ago | SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Po | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 36d ago | Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Adv | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 40d ago | Exploring the Impact of Diurnal Variation on Coagulation Function in P | N/A | ENROLLING_BY_INVITATION | ↗ |
| 42d ago | SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low R | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 44d ago | Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenv | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 48d ago | Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and B | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 48d ago | Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- B | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 48d ago | The Role of Total Abdominal Autonomic Nerve Preservation During the Re | N/A | ACTIVE_NOT_RECRUITING | ↗ |
| 49d ago | Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EG | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 51d ago | Clinical Value of CT Perfusion in Peripheral Artery Disease | N/A | NOT_YET_RECRUITING | ↗ |
| 51d ago | MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced No | Ph 2 | NOT_YET_RECRUITING | ↗ |
| 54d ago | PBI for Low-risk Breast Cancer | NA | RECRUITING | ↗ |
| 54d ago | FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy fo | Ph 3 | NOT_YET_RECRUITING | ↗ |
| 61d ago | AI-Assisted Patient Support in mHSPC | NA | NOT_YET_RECRUITING | ↗ |
| 61d ago | Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neo | NA | RECRUITING | ↗ |
Get this lane pushed to you the day a new grant or trial lands
Free email digest + a daily new-funding feed (JSON / MCP / webhook) of newly-awarded NIH grants and newly-registered clinical trials for Fudan University (trial sponsor). Watch institutions, PIs, sponsors, and topics. Newly-funded labs = new buyers, today.